La Jolla Pharmaceutical Co. (Nasdaq: LJPC) reported positive results from a Phase 2 clinical trial of its chronic kidney disease treatment GCS-100. The stock price leaped $7.06 to close at $17.96.
Positive Results For La Jolla Pharmaceutical
March 11, 2014 at 19:05 PM EDT
